1
|
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J. Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar ®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study. Exp Ther Med 2024; 27:51. [PMID: 38234624 PMCID: PMC10790165 DOI: 10.3892/etm.2023.12338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 07/14/2023] [Indexed: 01/19/2024] Open
Abstract
Essential hypertension is a notable threat for the older (age, ≥65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar®) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean ± standard error change of SeSBP/SeDBP was -10.3±0.8/-4.6±0.5 and -12.5±0.8/-5.6±0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P<0.001). Additionally, the satisfaction of both patients and physicians was elevated at W8 compared with at W0 (both P<0.001). The medication possession rate from baseline to W4 and W8 was 95.5 and 92.5%. The most common drug-associated adverse events by system organ classes were nervous system disorder (4.5%), vascular disorder (2.8%), and general disorder and administration site conditions (2.6%), which were generally mild. In conclusion, OM-AML tablets may be considered effective and safe in lowering BP, enabling the achievement of guideline-recommended BP targets in older Chinese patients with essential hypertension.
Collapse
Affiliation(s)
- Zhaoqiang Cui
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Zhaohui Qiu
- Department of Cardiology, Shanghai Tongren Hospital, Shanghai 200050, P.R. China
| | - Wenli Cheng
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China
| | - Wei Hu
- Department of Cardiology, Central Hospital of Minhang District, Shanghai 201199, P.R. China
| | - Genshan Ma
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu 210009, P.R. China
| | - Xiaojun Cai
- Department of Cardiology, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
| | - Yafei Jin
- Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510062, P.R. China
| | - Yi Zhao
- Department of Cardiology, Dalian Jinzhou First People's Hospital, Dalian, Liaoning 116199, P.R. China
| | - Liqun He
- Department of Cardiology, Wuhan No. 1 Hospital, Wuhan, Hubei 430030, P.R. China
| | - Ying Li
- Department of Cardiology, Shanghai East Hospital, Shanghai 200120, P.R. China
| | - Peili Bu
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong 250063, P.R. China
| | - Xiaoping Chen
- Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610044, P.R. China
| | - Ruxing Wang
- Department of Cardiology, Wuxi People's Hospital, Wuxi, Jiangsu 214023, P.R. China
| | - Lin Chen
- Department of Cardiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, P.R. China
| | - Peng Dong
- Department of Cardiology, Beijing Aviation General Hospital, Beijing 100123, P.R. China
| | - Liuliu Feng
- Department of Cardiology, Shidong Hospital, Shanghai 200090, P.R. China
| | - Xuebin Han
- Department of Cardiology, Shanxi Cardiovascular Hospital (Shanxi Cardiovascular Diseases Institute), Taiyuan, Shanxi 030024, P.R. China
| | - Mei Hong
- Department of Cardiology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210003, P.R. China
| | - Yinglong Hou
- Department of Cardiology, Shandong First Medical University, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, P.R. China
| | - Minlei Liao
- Department of Cardiology, Baoshan Branch, Shanghai General Hospital, Shanghai 201999, P.R. China
| | - Mingliang Wang
- Department of Cardiology, Shanghai Putuo District People's Hospital, Shanghai 200060, P.R. China
| | - Xiaoyan Wang
- Department of Cardiology, Hospital Affiliated Jiang Nan University, Wuxi, Jiangsu 214043, P.R. China
| | - Jianhong Xie
- Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 314408, P.R. China
| | - Yawei Xu
- Department of Cardiology, Shanghai Tenth People's Hospital, Shanghai 200072, P.R. China
| | - Zhenxing Wang
- Department of Cardiology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210004, P.R. China
| | - Kai Huang
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430073, P.R. China
| | - Yongle Li
- Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
| | - Dongsheng Li
- Department of Cardiology, Wuhan Third Hospital, Wuhan, Hubei 430074, P.R. China
| | - Xiaojun Ji
- Department of Cardiology, Wenzhou Central Hospital, Wenzhou, Zhejiang 325099, P.R. China
| | - Jing Huang
- Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
| | - Jun Wang
- Department of Cardiology, Jing'an District Central Hospital of Shanghai, Shanghai 200040, P.R. China
| | - Danhong Fang
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China
| | - Jian'an Wang
- Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China
| | - Lijiang Tang
- Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China
| | - Yingwu Liu
- Department of Cardiology, Tianjin Third Central Hospital, Tianjin 300170, P.R. China
| | - Guosheng Fu
- Department of Cardiology, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310020, P.R. China
| | - Juan Du
- Medical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai 200040, P.R. China
| | - Ling Wang
- Medical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai 200040, P.R. China
| | - Mengqi Liu
- Medical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai 200040, P.R. China
| | - Junbo Ge
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| |
Collapse
|
2
|
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J. Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study. J Clin Hypertens (Greenwich) 2024; 26:5-16. [PMID: 37667532 PMCID: PMC10795096 DOI: 10.1111/jch.14700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 07/02/2023] [Accepted: 07/03/2023] [Indexed: 09/06/2023]
Abstract
There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (±SE) change of SeSBP/SeDBP was -10.8 ± 0.4/-6.6 ± 0.3 mmHg at W4 and -12.7 ± 0.5/-7.6 ± 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension.
Collapse
Affiliation(s)
- Zhaoqiang Cui
- Department of CardiologyZhongshan Hospital, Fudan UniversityShanghaiChina
| | - Zhaohui Qiu
- Department of CardiologyShanghai Tongren HospitalShanghaiChina
| | - Wenli Cheng
- Department of CardiologyBeijing Anzhen Hospital, Capital Medical UniversityBeijingChina
| | - Wei Hu
- Department of CardiologyCentral Hospital of Minhang DistrictShanghaiChina
| | - Genshan Ma
- Department of CardiologyZhongda Hospital Affiliated to Southeast UniversityNanjingChina
| | - Xiaojun Cai
- Department of CardiologyJinan Central HospitalJinanChina
| | - Yafei Jin
- Department of CardiologyThe First Affiliated Hospital of Sun Yat‐sen UniversityGuangzhouChina
| | - Yi Zhao
- Department of CardiologyDalian Jinzhou First People's HospitalDalianChina
| | - Liqun He
- Department of CardiologyWuhan No. 1 HospitalWuhanChina
| | - Ying Li
- Department of CardiologyShanghai East HospitalShanghaiChina
| | - Peili Bu
- Department of CardiologyQilu Hospital of Shandong UniversityJinanChina
| | - Xiaoping Chen
- Department of CardiologyWest China Hospital of Sichuan UniversityChengduChina
| | - Ruxing Wang
- Department of CardiologyWuxi People's HospitalWuxiChina
| | - Lin Chen
- Department of CardiologyThird Affiliated Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Peng Dong
- Department of CardiologyBeijing Aviation General HospitalBeijingChina
| | - Liuliu Feng
- Department of CardiologyShidong Hospital, Yangpu DistrictShanghaiChina
| | - Xuebin Han
- Department of CardiologyShanxi Cardiovascular Hospital (Shanxi Cardiovascular Diseases Institute)TaiyuanChina
| | - Mei Hong
- Department of CardiologyThe Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Yinglong Hou
- Department of CardiologyThe First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalJinanChina
| | - Minlei Liao
- Department of CardiologyBaoshan Branch, Shanghai General HospitalShanghaiChina
| | - Mingliang Wang
- Department of CardiologyPutuo People's Hospital, Tongji UniversityShanghaiChina
| | - Xiaoyan Wang
- Department of CardiologyWuxi Third People's HospitalWuxiChina
| | - Jianhong Xie
- Department of CardiologyZhejiang Provincial People's HospitalHangzhouChina
| | - Yawei Xu
- Department of CardiologyShanghai Tenth People's HospitalShanghaiChina
| | - Zhenxing Wang
- Department of CardiologyJiangsu Province Hospital of Chinese MedicineNanjingChina
| | - Kai Huang
- Department of CardiologyUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhanChina
| | - Yongle Li
- Department of CardiologyTianjin Medical University General HospitalTianjinChina
| | - Dongsheng Li
- Department of CardiologyWuhan Third HospitalWuhanChina
| | - Xiaojun Ji
- Department of CardiologyWenzhou Central HospitalWenzhouChina
| | - Jing Huang
- Department of CardiologyThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina
| | - Jun Wang
- Department of CardiologyJing'an District Central Hospital of ShanghaiShanghaiChina
| | - Danhong Fang
- Department of CardiologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
| | - Jian'an Wang
- Department of CardiologyThe Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina
| | - Lijiang Tang
- Department of CardiologyZhejiang HospitalHangzhouChina
| | - Yingwu Liu
- Department of CardiologyTianjin Third Central HospitalTianjinChina
| | - Guosheng Fu
- Department of CardiologySir Run Run Shaw Hospital of Zhejiang University School of MedicineHangzhouChina
| | - Juan Du
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Ling Wang
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Mengqi Liu
- Medical DepartmentDaiichi Sankyo (China) Holdings Co., LtdShanghaiChina
| | - Junbo Ge
- Department of CardiologyZhongshan Hospital, Fudan UniversityShanghaiChina
| |
Collapse
|
3
|
Zhang Z, Xie M, Dai X, Duan Z, Lu Z, Cai L, Gu R, Shen L, Xu Z, Yao W, Liu Y, Liao M, Shi H. The prognostic value and economic benefits of coronary angiography-derived fractional flow reserve-guided strategy in patients with coronary artery disease. Heliyon 2023; 9:e17464. [PMID: 37416633 PMCID: PMC10320262 DOI: 10.1016/j.heliyon.2023.e17464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 06/17/2023] [Accepted: 06/19/2023] [Indexed: 07/08/2023] Open
Abstract
Objective This study aims to investigate the prognostic value and economic benefit of coronary angiography-derived fractional flow reserve (caFFR) guided percutaneous coronary intervention (PCI) in patients with coronary artery disease. Methods All patients with coronary artery disease (CAD) who underwent coronary angiography in our center between April 2021 and November 2021 were retrospectively enrolled and divided into the caFFR guidance group (n = 160) and angiography guidance group (n = 211). A threshold of caFFR≤0.8 was used for revascularization. Otherwise, delayed PCI was preferred. The patients were prospectively followed up by telephone or outpatient service at six months for major adverse cardiovascular events (MACE) of all-cause death, myocardial infarction or target vessel revascularization, stent thrombosis, and stroke. All in-hospital expenses were recorded, including initial hospitalization and re-hospitalization related to MACE. Results There was no significant difference in the baseline characteristics between the two groups. There were 2 (1.2%) patients in the caFFR guidance group and 5 (2.4%) patients in the angiography guidance group with MACE events during the following six months. Compared with angiography guidance, caFFR guidance reduced the revascularization rate (63.7% vs. 84.4%, p = 0.000), the average length of stents implanted (0.52 ± 0.88 vs. 1.1 ± 1.4, P < 0.001). The cost of consumables in the caFFR guidance group was significantly lower than that in the angiography guidance group (33257 ± 19595 CNY vs. 38341 ± 16485 CNY, P < 0.05). Conclusion Compared with coronary angiography guidance, caFFR guidance is of great significance in reducing revascularization and cost, which has significant health and economic benefits.
Collapse
Affiliation(s)
- Zhenzhou Zhang
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Mengshi Xie
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Xixi Dai
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Zhiyong Duan
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Zhiren Lu
- Medical Emergency Center of Baoshan District, Shanghai, 201901, China
| | - Liangyin Cai
- Department of Pharmacy, Wusong Hospital of Zhongshan Hospital, Fudan University, 200094, China
| | - Rongrong Gu
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Lei Shen
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Zhong Xu
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Weifeng Yao
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Yunfei Liu
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Minlei Liao
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| | - Hongyu Shi
- Department of Cardiology, Zhongshan Hospital Wusong Branch, Fudan University, 200094, China
| |
Collapse
|
4
|
Liao M, Shang XK, Zhang CD, Chen S. [Progress on the application of transcatheter pulmonary valve replacement in autogenous right ventricular outflow tract pulmonary valve regurgitation]. Zhonghua Xin Xue Guan Bing Za Zhi 2022; 50:830-834. [PMID: 35982020 DOI: 10.3760/cma.j.cn112148-20220702-00510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Affiliation(s)
- M Liao
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - X K Shang
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - C D Zhang
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - S Chen
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| |
Collapse
|
5
|
Chen B, Xi S, El-Senousey HAK, Zhou M, Cheng D, Chen K, Wan L, Xiong T, Liao M, Liu S, Mao H. Deletion in KRT75L4 linked to frizzle feather in Xiushui Yellow Chickens. Anim Genet 2021; 53:101-107. [PMID: 34904261 DOI: 10.1111/age.13158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2021] [Indexed: 11/30/2022]
Abstract
Bird feathers are the product of interactions between natural and artificial selection. Feather-related traits are important for chicken selection and breeding. Frizzle feather is characterized by the abnormally development of feathers in chickens. In the current study, frizzle feather characteristics were observed in a local breed called Xiushui Yellow Chicken in Jiangxi, China. To determine the molecular mechanisms that underlie frizzle feather in Xiushui Yellow Chicken, four populations of three breeds (Xiushui Yellow Chicken with frizzle feathers, Xiushui Yellow Chicken with normal feathers, Guangfeng White-Ear Yellow Chicken, and Ningdu Yellow Chicken) were selected for whole-genome resequencing. Using a comparative genome strategy and genome-wide association study, a missense mutation (g.5281494A>G) and a 15-bp deletion (g.5285437-5285451delGATGCCGGCAGGACG) in KRT75L4 were identified as candidate mutations associated with frizzle feather in Xiushui Yellow Chicken. Based on genotyping performed in a large Xiushui Yellow Chicken population, the g.5285437-5285451delGATGCCGGCAGGACG mutation in KRT75L4 was confirmed as the putative causative mutation of frizzle feather. These results deepen the understanding of the molecular mechanisms responsible for frizzle feather, as well as facilitating the molecular detection and selection of the feather phenotype in Xiushui Yellow Chickens.
Collapse
Affiliation(s)
- B Chen
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - S Xi
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China.,Jiangxi Biotech Vocational College, Nanchang, Jiangxi, 330200, China
| | - H A K El-Senousey
- Department of Animal Production, Faculty of Agriculture, Cairo University, Giza, 12613, Egypt
| | - M Zhou
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - D Cheng
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - K Chen
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - L Wan
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - T Xiong
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - M Liao
- School of Foreign Languages, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - S Liu
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| | - H Mao
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, 330045, China
| |
Collapse
|
6
|
Peng X, Li YJ, Yau YQ, Liao M, Liu KC, Yuan RL, Cao ZQ, Tang XB, Xu Y, Liang JW, Li QX, Wang H. [Treatment efficacy of dietary supplement Licofor for dry eye associated with meibomian gland dysfunction]. Zhonghua Yi Xue Za Zhi 2021; 101:2508-2513. [PMID: 34407575 DOI: 10.3760/cma.j.cn112137-20210228-00508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the clinical efficacy of dietary supplement Licofor in the treatment of dry eye associated with meibomian gland dysfunction (MGD). Methods: This was a prospective, randomized controlled clinical trial. Sixty patients [25 males, 35 females, aged (42±13) years] who had dry eye associated with MGD were recruited in Xiangya Hospital of Central South University from December 2018 to October 2019. The patients were equally divided into two groups: 30 cases (60 eyes) in the experimental group and 30 cases (60 eyes) in the control group. All subjects were treated with eye hot compress, artificial tears and antibiotic ointment. After that, the experimental group and control group were received dietary supplementary Licofor or placebo daily for 12 weeks. The symptoms and signs of dry eye, morphology and function of meibomian gland, and inflammatory response were assessed at the beginning, 4th, 8th and 12th week of treatment. Results: After 12 weeks of treatment, statistically significant improvements in ocular surface disease index (OSDI) scores, tear break-up time (TBUT), corneal fluorescein staining (CFS), the morphology of eyelid margin, meibomian gland orifice, meibomian gland expressibility, meibum quality, and periglandular inflammatory cell density were determined in both groups (all P<0.05). In the Licofor group, the improvement of OSDI scores [16.7 (12.5, 20.8) vs 20.8 (18.8, 22.9), P<0.001], the morphology of eyelid margin, meibomian gland orifice and periglandular inflammatory cell density [443 (318, 513) vs 553 (415, 676)/mm2, P=0.002] were more significant (all P<0.05). Conclusion: The combined treatment of licofor and conventional treatment can significantly improve symptoms of dry eye, the morphology of eyelid margin, meibomian gland orifice, meibum quality, and eyelid inflammation response of dry eye associated with MGD.
Collapse
Affiliation(s)
- X Peng
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - Y J Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China
| | - Y Q Yau
- Department of Ophthalmology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong 999077, China
| | - M Liao
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - K C Liu
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - R L Yuan
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - Z Q Cao
- Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
| | - X B Tang
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - Y Xu
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - J W Liang
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| | - Q X Li
- Ningxia Geriatric Disease Clinical Research Center, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan 750001, China
| | - H Wang
- Eye Center of Xiangya Hospital, Central South University, Hunan Key Laboratory of Ophthalmology, Changsha 410008, China
| |
Collapse
|
7
|
Xuan YW, Liao M, Zhai WL, Peng LJ, Tang Y. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. Eur Rev Med Pharmacol Sci 2020; 23:8411-8421. [PMID: 31646571 DOI: 10.26355/eurrev_201910_19152] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To investigate the role of miR-381 in the progression of lung adenocarcinoma (LA) and its underlying mechanism. PATIENTS AND METHODS A total of 54 pairs of LA tissues and para-carcinoma tissues were obtained from May 2015 to April 2017 in our hospital. Four human LA cell lines (A549, SPC-A1, H1299, and PC-9) and one normal human pulmonary epithelial cell line BEAS-2B were obtained and cultured. The protein and mRNA expression levels were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot, respectively. Additionally, cell proliferation assays and cell migration and invasion assays were used. Furthermore, tumor xenograft model in nude mice was made in this study. RESULTS miR-381 was notably downregulated in LA tissues. Moreover, low miR-381 expression was confirmed to be strongly correlated with poor prognosis and aggressive clinicopathological characteristics of LA patients. Exogenous miR-381 overexpression was found to notably restrict LA cell proliferation, migration, and invasion; additionally, miR-381 overexpression could significantly reduce tumor growth in vivo. Mechanistically, LMO3 was determined as a novel direct target for miR-381 in LA cells. In clinical LA tissues, the LMO3 expressions were clearly overexpressed. Furthermore, miR-381 overexpression affected the PI3K/Akt pathway and EMT in LA. CONCLUSIONS MiR-381 played key roles in LA progression, partially via directly targeting LMO3 and regulating the PI3K/Akt signaling pathway and EMT. Thus, the miR-381/ LMO3 axis has clinical significance in the therapy of patients with LA.
Collapse
Affiliation(s)
- Y-W Xuan
- Department of Thoracic Surgery, General Hospital of Southern Theatre Command, Guangzhou, China.
| | | | | | | | | |
Collapse
|
8
|
Chen J, Mao YY, Chen Z, Liao M, Li S, Liu JY, Yang YC. [Research progress on the role of type Ⅱ inflammation in chronic rhinosinusitis with polyps]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 55:993-997. [PMID: 33036521 DOI: 10.3760/cma.j.cn115330-20200813-00671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J Chen
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - Y Y Mao
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - Z Chen
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - M Liao
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - S Li
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - J Y Liu
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| | - Y C Yang
- Department of Otolaryngology, First Affiliated Hospital of Chongqing Medical University, First Clinical Medical College of Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
9
|
Hamilton E, Patel M, Gunderson C, Wride K, Lepley D, Dusek R, Liao M, Cameron T. 556P Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.670] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Dai Y, Li ZP, Xu H, Zhu L, Zhu YQ, Cheng H, Chen ZB, Huang QZ, Lei L, Li RQ, Li G, Li Y, Liao M, Lu QH, Shi XP, Sun HJ, Shi TL, Wu XX, Wang ZS, Xu J, Zhao G, Zhang GY, Chen C. [A multicenter survey of the accessibility of essential medicines for children in China]. Zhonghua Er Ke Za Zhi 2020; 58:301-307. [PMID: 32234137 DOI: 10.3760/cma.j.cn112140-20190820-00527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the availability, prices and affordability of essential medicines in pediatric population across China, in the hope of improving rational use of medicines. Methods: A multicenter cross-sectional survey of medicine prices, availability and affordability was conducted in 17 provinces, municipalities and autonomous region across east, south-central part, west and north of China. Data on 42 medicines used in pediatric population, both original and generic, were collected in 55 public hospitals from May 26 to June 2, 2017. Availability was expressed as the percentage of hospitals with stock of the target medicine on the day of data collection,and median price ratio (MPR) was the ratio of price upon investigation to international reference. Based on national minimum daily wage, affordability represents the number of working days needed to earn the expense which covers a standard course using the target medicine. Statistical software SPSS 13.0 was applied for descriptive analysis of availability, MPR and affordability. Results: Mean Availability of original and generic medicine was 33% and 32%, with median MPR being 5.43 and 1.55. Among the 19 medicines with price information for both original and generic product, the median MPR was 7.73 and 2.04 respectively. Regarding the five medicines used to treat four common pediatric diseases (pneumonia,peptic ulcer, congenital hypothyroidism, refractory nephrotic syndrome), the affordability was 0.63 (0.16-6.17) d for generic medicine, and 1.03 (0.16-11.53) d for its original counterpart. Conclusions: The availability to both original and generic products of the 42 medicines used in pediatric population was low in China. The prices of generic medicines seem to be lower and affordability higher than those of original medicines. There is an urgent need to improve the availability and affordability of pediatric medicines.
Collapse
Affiliation(s)
- Y Dai
- Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China
| | - Z P Li
- Department of Pharmacy, Children's Hospital of Fudan University,Shanghai 201102, China
| | - H Xu
- Department of Nephrology, Children's Hospital of Fudan University,Shanghai 201102, China
| | - L Zhu
- Department of Pharmacy, Children's Hospital of Fudan University,Shanghai 201102, China
| | - Y Q Zhu
- Department of Pharmacy, Children's Hospital of Fudan University,Shanghai 201102, China
| | - H Cheng
- Department of Pharmacy, Xi'an Children's Hospital, Xi'an 710003, China
| | - Z B Chen
- Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen 518038, China
| | - Q Z Huang
- Department of Pharmacy, Fuzhou Children's Hospital, Fuzhou 350005, China
| | - L Lei
- Department of Pharmacy, Children's Hospital of Urumqi, Urumqi 830000, China
| | - R Q Li
- Department of Pharmacy, Kunming Children's Hospital, Kunming 650228, China
| | - G Li
- Department of Pharmacy, Chengdu Women's and Children's Central Hospital, Chengdu 610091, China
| | - Y Li
- Department of Pharmacy, Qingdao Women and Children's Hospital, Qingdao 266000, China
| | - M Liao
- Department of Pharmacy, Guiyang Maternal and Child Health Hospital, Guiyang 550003, China
| | - Q H Lu
- Department of Pharmacy, Jiangxi Provincial Children's Hospital, Nanchang 330006, China
| | - X P Shi
- Department of Pharmacy, Dalian Children's Hospital,Dalian 116012,China
| | - H J Sun
- Department of Pharmacy, Children's Hospital of Shanghai, Shanghai 200062, China
| | - T L Shi
- Department of Pharmacy, the First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei 230001,China
| | - X X Wu
- Department of Pharmacy, Qilu Children's Hospital of Shandong University, Jinan 250022,China
| | - Z S Wang
- Department of Pharmacy, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - J Xu
- Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210019, China
| | - G Zhao
- Department of Pharmacy, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning 530003, China
| | - G Y Zhang
- Department of Pharmacy, Hebei Children's Hospital, Shijiazhuang 050031, China
| | - C Chen
- Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, China
| |
Collapse
|
11
|
Kiang S, Tritch W, Lodenkamp J, Adams J, Liao M, Abou-zamzam A, Tomihama R. 3:00 PM Abstract No. 42 Analysis of microchannel recanalization with orbital atherectomy in failed standard recanalization of TASC-II D aortoiliac occlusive disease. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
12
|
Moriarty J, Rueda V, Liao M, Srinivasa R, Plotnik A, Padia S, McWilliams J, Patel R, Desai K, Shavelle D, Dexter D, Golowa Y. 3:45 PM Abstract No. 287 Results of Registry of AngioVac Procedures in Detail (RAPID): prospective multicenter real-world experience in 206 patients with 214 procedures. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
13
|
Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol 2019; 21:134-144. [PMID: 31780255 DOI: 10.1016/s1470-2045(19)30693-x] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 09/23/2019] [Accepted: 09/26/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Atezolizumab is an inhibitor of PD-L1, which can lead to enhanced anticancer T-cell activity. We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in children and young adults with refractory or relapsed solid tumours, with known or expected PD-L1 expression. METHODS iMATRIX was a multicentre, open-label, phase 1-2 trial of patients (aged <30 years) with solid tumours or lymphomas recruited from 28 hospitals in ten countries (USA, France, Italy, UK, Spain, the Netherlands, Denmark, Israel, Switzerland, and Germany). Eligible patients younger than 18 years received 15 mg/kg atezolizumab (maximum 1200 mg); patients aged 18-29 years received the adult dose (1200 mg) until disease progression or loss of clinical benefit. Co-primary endpoints were safety (assessed by incidence of adverse events) and pharmacokinetics (assessed by serum atezolizumab concentrations). Secondary endpoints included the proportion of patients achieving an objective response. This trial is registered with ClinicalTrials.gov, number NCT02541604. FINDINGS Between Nov 5, 2015, and April 2, 2018, we screened 115 patients, 25 of whom did not meet the inclusion criteria. 90 patients, with a median age of 14 years (IQR 10-17), were enrolled. At the data cutoff (April 2, 2018), two patients remained on study treatment. 87 (97%) of 90 patients received at least one dose of atezolizumab at 15 mg/kg or 1200 mg and were evaluable for safety. Three patients were not treated owing to either poor clinical condition or withdrawal of consent. In the safety-evaluable population (n=87), the most common adverse events were pyrexia (36 [41%] patients) and fatigue (31 [36%]). The most common grade 3-4 adverse event was anaemia (19 [22%] patients). The most commonly reported serious adverse events were in the categories of infections and infestations; pyrexia was the only serious adverse event reported in more than two patients. 57 (66%) patients had at least one treatment-related adverse event (grade 1-4); fatigue was the most common treatment-related adverse event (17 patients [20%]). There were no fatal adverse events. Mean serum concentrations of atezolizumab were overlapping and comparable between children receiving 15 mg/kg and young adults receiving 1200 mg of atezolizumab every 3 weeks. Serum concentrations of atezolizumab were above the target exposure level in all patients. At 6 months, four patients (5%) achieved an objective response (all partial responses). INTERPRETATION Although response to atezolizumab was restricted, atezolizumab was well tolerated with generally comparable exposure across populations. Our findings might help to define future development strategies for immune checkpoint inhibitors either by focusing research to specific disease subpopulations that exhibit greater benefit from immune checkpoint inhibitors, or by providing the means to identify therapeutic combination partners that augment T-cell infiltration and proliferation in so-called immune cold tumour microenvironments. FUNDING F Hoffmann-La Roche.
Collapse
Affiliation(s)
- Birgit Geoerger
- Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.
| | - C Michel Zwaan
- Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands; Princess Máxima Center, Utrecht, Netherlands
| | - Lynley V Marshall
- Paediatric and Adolescent Oncology Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - Jean Michon
- Service de Pédiatrie, SIREDO Center, Curie Institute, Paris, France
| | - Franck Bourdeaut
- Service de Pédiatrie, SIREDO Center, Curie Institute, Paris, France
| | | | - Nadège Corradini
- Haematology and Oncology Paediatric Institut, Léon Bérard Centre, Lyon, France
| | | | | | | | | | | | | | | | - Tanya Trippett
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
14
|
Hutchinson KE, Liao M, Farid-Kapadia M, Donaldson F, Tam NWR, Fu LH, Thakur MD, Zwaan CM, Geoerger B, Marshall LV, Trippett T, Rossato G. Abstract 3114: Correlation between response to atezolizumab and PD-L1 tumor expression in pediatric and young adult patients enrolled in the phase I/II iMATRIX-atezo study. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction The iMATRIX-atezo trial (NCT02541604) assessed the safety and pharmacokinetics (primary objectives) and preliminary activity (secondary objective) of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors, including Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Atezolizumab targets PD-L1 expressed by tumor cells leading to an enhanced anticancer T-cell response. The purpose of this analysis was to investigate the association between PD-L1 expression and response to atezolizumab in patients participating in the iMATRIX-atezo trial.
Methods Patients aged <30 years received atezolizumab every 3 weeks until loss of clinical benefit. Biomarkers were analyzed across cohorts and by response to atezolizumab, with a minimum follow up of 6 months. Response was assessed by RECIST, modified International Neuroblastoma Response Criteria, Response Criteria for Malignant Lymphoma, and RANO. Pretreatment tissues were examined by immunohistochemistry for: T/B/NK cell markers, tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in tumor cells [TC] and immune cells [IC]. Blood samples were analyzed for T/B/NK cell constitution by flow cytometry. Tumor mutational burden (TMB) was determined by FoundationOne® next-generation sequencing.
Results Eighty-seven patients received ≥1 dose of atezolizumab. Of 11 patients with high PD-L1 expression (TC2/TC3/IC2/IC3) and response data, four had a partial response (PR; two with HL, one with NHL, one with a rhabdoid tumor), one had stable disease (SD) and six had progressive disease (PD). Of 52 patients with low or no PD-L1 expression (TC1/TC0/IC1/IC0) and response data, no responses were observed. Though numerically limited, PD-L1 expression and response were significantly correlated (p=0.0006, Fisher’s exact test). HL (8/9 patients) and NHL (2/3 patients) cohorts had the greatest proportion of patients with high baseline PD-L1. Levels of CD8+ (T cells), CD20+ (B cells) and stromal TILs at baseline were significantly associated with patients’ response status (p<0.05, Mann-Whitney U test). High PD-L1 expression correlated with elevated expression of other tissue-based immune biomarkers, except NK cells. Blood biomarkers did not correlate with tumor-based counterparts. No tumors were TMB high; all were <16 mutations/megabase.
Conclusions High PD-L1 expression compared with low or no expression was associated with a greater response to atezolizumab, notably in patients with HL and NHL. Despite small sample sizes and limited responses, these biomarker data support adult studies citing the association between PD-L1 and response to atezolizumab; data suggest that PD-L1 may also be a predictor of atezolizumab response in pediatric and young adult patients.
Citation Format: Katherine E. Hutchinson, Minlei Liao, Mufiza Farid-Kapadia, Francis Donaldson, Nga Wan Rachel Tam, Lingyan Helen Fu, Meghna Das Thakur, C. Michel Zwaan, Birgit Geoerger, Lynley V. Marshall, Tanya Trippett, Gianluca Rossato. Correlation between response to atezolizumab and PD-L1 tumor expression in pediatric and young adult patients enrolled in the phase I/II iMATRIX-atezo study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3114.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - C. Michel Zwaan
- 4Erasmus MC-Sophia Children’s Hospital & Princess Máxima Center, Rotterdam/Utrecht, Netherlands
| | | | - Lynley V. Marshall
- 6The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
| | | | | |
Collapse
|
15
|
Xu C, Ye H, Qiu W, Lin H, Chen Y, Zhang H, Liao M. Phylogenetic classification of hemagglutinin gene of H9N2 avian influenza viruses isolated in China during 2012-2016 and evaluation of selected candidate vaccine strains. Poult Sci 2018; 97:3023-3030. [PMID: 29931183 DOI: 10.3382/ps/pey154] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 06/13/2018] [Indexed: 12/20/2022] Open
Abstract
H9N2 subtype avian influenza virus (AIV) was the highly contagious pathogen which has caused severe losses in the poultry industry throughout China in recent years. Using current epidemic viruses as vaccine was an effective way to prevent infection of H9N2 subtype AIV. In this study, a total of 23 H9N2 subtype AIV strains were isolated in 200 samples from 13 provinces of China during 2012-2016. The sequencing and phylogenetic analysis of the hemagglutinin gene sequence of the isolation strains showed that 22 isolation strains were clustered to h9.4.2.5 lineage, while only 1 belonged to h9.4.2.6. The data of cross-HI, neutralization and cross-immune protection shown that the A/chicken/Hunan/HN/2015 (HN) and A/chicken/Shandong/SD/2014 (SD) strains as vaccine could effectively protect present viruses infection compared with other strains. These results indicated that current epidemic viruses were mainly belong to h9.4.2.5 lineage and HN and SD strains as candidate vaccine strains were potentiality for the protection of present H9N2 subtype AIV infection.
Collapse
Affiliation(s)
- C Xu
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Key Laboratory of Veterinary Vaccine Innovation of the Ministry of Agriculture, China.,Key Laboratory of Zoonosis Prevention and Control of Guangzhou Province, China
| | - H Ye
- Guangzhou South China Biological Medicine Co., Ltd., Zengcheng, China
| | - W Qiu
- Guangzhou South China Biological Medicine Co., Ltd., Zengcheng, China
| | - H Lin
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - Y Chen
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - H Zhang
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - M Liao
- National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Key Laboratory of Veterinary Vaccine Innovation of the Ministry of Agriculture, China.,Key Laboratory of Zoonosis Prevention and Control of Guangzhou Province, China
| |
Collapse
|
16
|
Vance A, Graif A, Grilli C, Nwosu U, Liao M, Agriantonis D, Kimbiris G, Garcia M, Leung D. Abstract No. 639 Outcome of iliocaval stent-assisted reconstruction in patients with chronic obstruction of the inferior vena cava. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
17
|
Chen J, Zhang H, Zhu D, Wang Y, Byanju S, Liao M. Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation. Herz 2018; 44:390-397. [DOI: 10.1007/s00059-017-4676-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 11/14/2017] [Accepted: 12/21/2017] [Indexed: 01/04/2023]
|
18
|
Liao M, Yeh C, Lee S, Lee M. ASSOCIATION OF SUPPORT ON THE MORTALITY OF OLDER ADULTS WITH DIFFERENT LIVING ARRANGEMENTS IN TAIWAN. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M. Liao
- Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan,
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan,
| | - C. Yeh
- School of Public Health, Chung Shan Medical University, Taichung, Taiwan,
| | - S. Lee
- School of Nursing, Chung Shan Medical University, Taichung, Taiwan
| | - M. Lee
- Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan,
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan,
| |
Collapse
|
19
|
Chou M, Huang T, Liang C, Shen H, Chen H, Liao M, Lin Y, Lam H. DYNAPENIA IS A SIMPLE INDICATOR FOR COMPLEX CARE NEEDS OF OLDER MEN IN VETERANS CARE HOMES IN TAIWAN. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M. Chou
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
- Aging and Health Research Center, National Yang Ming University, Taipei City, N/A, Taiwan,
| | - T. Huang
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
- Department of Family Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, N/A, Taiwan
| | - C. Liang
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
- Aging and Health Research Center, National Yang Ming University, Taipei City, N/A, Taiwan,
| | - H. Shen
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
| | - H. Chen
- Department of Family Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, N/A, Taiwan
| | - M. Liao
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
| | - Y. Lin
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
| | - H. Lam
- Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
| |
Collapse
|
20
|
Tang W, Mao J, Liu C, Mollan K, Wong T, Zhang Y, Tang S, Hudgens M, Qin Y, Ma B, Liao M, Yang B, Ma W, Kang D, Wei C, Tucker J. Reimagining Health Communication: A Non-Inferiority Randomized Controlled
Trial of Crowdsourcing in China. Ann Glob Health 2017. [DOI: 10.1016/j.aogh.2017.03.371] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
21
|
Zhang Z, Li Z, Yu Q, Wu C, Lu Z, Zhu F, Zhang H, Liao M, Li T, Chen W, Xian X, Tan A, Mo Z. The prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction in Chinese men. Andrology 2016; 3:1119-24. [PMID: 26769668 DOI: 10.1111/andr.12104] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 07/14/2015] [Accepted: 08/12/2015] [Indexed: 11/29/2022]
Abstract
The aim of this study was to describe the prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction (ED) among southern Chinese men. Data were collected from 2790 men attending the Fangchenggang Area Male Healthy and Examination Survey from September 2009 to December 2009. The prostatitis-like symptoms were assessed by the NIH Chronic Prostatitis Symptom Index and ED was assessed using the 5-item International Index of Erectile Function. Lifestyle and demographic characteristics were obtained through a questionnaire. Prevalence of prostatitis-like symptoms was 12.4% among 2790 Chinese men aged 20-84 years. In smokers who smoked ≥20 cigarettes per day (age-adjusted OR = 1.29; 95% CI = 1.00-1.66; p = 0.04), physical inactivity (age-adjusted OR = 1.31; 95% CI = 1.03-1.66; p = 0.02) was a significant risk factor for prostatitis-like symptoms. Alcohol consumption (daily drinking) also was a risk factor for prostatitis-like symptoms, although the differences were not statistically significant (age-adjusted OR = 1.36; 95% CI = 0.96-1.92; p = 0.07). Those with diabetes may also be at higher risk for prostatitis-like symptoms (age-adjusted OR = 1.37; 95% CI = 0.85-2.21; p = 0.19). In addition, men with ED were more likely to have had prostatitis-like symptoms (age-adjusted OR = 1.86; 95% CI = 0.47-2.36; p < 0.0001), and the ORs increased with increasing severity of ED status (mild ED, mild to moderate ED, and moderate to severe ED were 1.57, 2.62, and 3.24, respectively. Test for trend, p = 0.0001). Our results show that prostatitis-like symptoms are prevalent in Southern China affecting men of all ages. Smoking, drinking, lack of physical activity, and elevated plasma glucose level were associated with an increased risk of prostatitis-like symptoms. In addition, our results reveal that ED accounted for a large proportion (61.5%) among men with prostatitis-like symptoms; we also confirm the magnitude of ED associated with prostatitis-like symptoms. Thus, interventions to evaluate and improve ED might help ameliorate prostatitis-like symptoms and vice versa.
Collapse
Affiliation(s)
- Z Zhang
- Urology Department, Minzu Hospital of Guangxi Zhuang Autonomous Region, Affiliated Minzu Hospital of Guangxi Medical University, Nanning, China.,Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
| | - Z Li
- Urology Department, The Armed Police Corps Hospital of Guangdong Provence, Guangzhou, China
| | - Q Yu
- Urology Department, First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China
| | - C Wu
- Urology Department, First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China
| | - Z Lu
- Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - F Zhu
- Urology Department, First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China
| | - H Zhang
- Urology Department, First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China
| | - M Liao
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.,Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - T Li
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.,Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - W Chen
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.,Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - X Xian
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.,Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - A Tan
- Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Z Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.,Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
| |
Collapse
|
22
|
Wei L, Song Y, Cui J, Qu N, Wang N, Ouyang G, Liao M, Jiao P. Cloning, characterization, and expression analysis of LGP2 cDNA from goose, Anser cygnoides. Poult Sci 2016; 95:2290-6. [DOI: 10.3382/ps/pew162] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Accepted: 03/23/2016] [Indexed: 01/21/2023] Open
|
23
|
Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE. Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord 2016; 17:261. [PMID: 27301458 PMCID: PMC4908678 DOI: 10.1186/s12891-016-1102-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2015] [Accepted: 05/27/2016] [Indexed: 01/21/2023] Open
Abstract
Background Real-world data regarding anti-tumor necrosis factor alpha (anti-TNFα) biologic therapy use in psoriatic arthritis (PsA) are limited; therefore, we described treatment patterns and costs of anti-TNFα therapy in PsA patients in the United States. Methods PsA patients (N = 990) aged ≥18 years who initiated anti-TNFα therapy were selected from MarketScan claims databases (10/1/2009 to 9/30/2010). Number of patients on first- (n = 881), second- (n = 72), or third- or greater (n = 37) line of anti-TNFα therapy, persistence, time-to-switch or modification, pharmacy and medical costs (measured per patient per month [PPPM]) for each line of therapy were observed during the 3-year follow-up. Results PsA patients receiving only one line of anti-TNFα therapy remained on first-line for ~17 months while those who switched to second- or third- or greater persisted on first-line for ~11 to 12 months, respectively. Time to first-line modification was longer for patients who switched to third- or greater line therapy (7 months) than those who did not switch or switched to second-line (range, ~2 to 4 months). Time-to-switch and time to first-line modification was progressively shorter with each line of therapy for patients who received third- or greater line. PPPM medical costs were higher for patients who did not switch ($322) than those who switched to second- ($167) or third- or greater ($217) line. PPPM pharmacy costs were greater for patients with third- or greater line therapy ($2539) than those who did not switch ($1985) or switched to second-line ($2045). Conclusion While the majority of patients received only one line of anti-TNFα therapy, a subset of patients switched to multiple lines of therapy during the 3-year follow-up period. Persistence and therapy modifications differed between these patients and those receiving only one line. Overall medical costs were highest for patients who did not switch, and pharmacy costs increased as patients switched to each new line of therapy.
Collapse
Affiliation(s)
- Jacqueline B Palmer
- Immunology and Dermatology, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
| | - Yunfeng Li
- Outcomes Research Methods & Analytics, US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936-1080, USA
| | - Vivian Herrera
- Immunology and Dermatology, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA
| | - Minlei Liao
- KMK Consulting, Inc, Morristown, NJ, 07960-1080, USA
| | - Melody Tran
- Immunology and Dermatology, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.,Scott & White Health Plan, Temple, TX/College of Pharmacy, The University of Texas at Austin, Austin, TX, 78705, USA
| | - Zafer E Ozturk
- Immunology and Dermatology Medical Affairs Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936-1080, USA
| |
Collapse
|
24
|
Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer DG, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Erich Eberhardt WE, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom EM, van Meerbeeck J, Mitchell A, Nakano T, Nicholson AG, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF, Travis W, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Erasmus J, Flieder D, Godoy M, Goo JM, Goodman LR, Jett J, de Leyn P, Marchevsky A, MacMahon H, Naidich D, Okada M, Perlman M, Powell C, van Schil P, Tsao MS, Warth A, Cavaco FA, Barrera EA, Arca JA, Lamelas IP, Obrer AA, Jorge RG, Ball D, Bascom G, Blanco Orozco A, González Castro M, Blum M, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Escobar Campuzano I, Macía Vidueira I, Fernández Araujo E, Andreo García F, Fong K, Francisco Corral G, Cerezo González S, Freixinet Gilart J, García Arangüena L, García Barajas S, Girard P, Goksel T, González Budiño M, González Casaurrán G, Gullón Blanco J, Hernández J, Hernández Rodríguez H, Herrero Collantes J, Iglesias Heras M, Izquierdo Elena J, Jakobsen E, Kostas S, León Atance P, Núñez Ares A, Liao M, Losanovscky M, Lyons G, Magaroles R, De Esteban Júlvez L, Mariñán Gorospe M, McCaughan B, Kennedy C, Melchor Íñiguez R, Miravet Sorribes L, Naranjo Gozalo S, Álvarez de Arriba C, Núñez Delgado M, Padilla Alarcón J, Peñalver Cuesta J, Park J, Pass H, Pavón Fernández M, Rosenberg M, Ruffini E, Rusch V, Sánchez de Cos Escuín J, Saura Vinuesa A, Serra Mitjans M, Strand T, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, Van Schil P, Velasquez M, Wu Y, Yokoi K. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol 2016; 11:639-650. [DOI: 10.1016/j.jtho.2016.01.024] [Citation(s) in RCA: 111] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 01/20/2016] [Accepted: 01/21/2016] [Indexed: 12/25/2022]
|
25
|
Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, Rami-Porta R, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer DG, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Erich Eberhardt WE, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom EM, van Meerbeeck J, Mitchell A, Nakano T, Nicholson AG, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF, Travis W, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Erasmus J, Flieder D, Godoy M, Goo JM, Goodman LR, Jett J, de Leyn P, Marchevsky A, MacMahon H, Naidich D, Okada M, Perlman M, Powell C, van Schil P, Tsao MS, Warth A, Cavaco FA, Barrera EA, Arca JA, Lamelas IP, Obrer AA, Jorge RG, Ball D, Bascom G, Blanco Orozco A, González Castro M, Blum M, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Escobar Campuzano I, Macía Vidueira I, Fernández Araujo E, Andreo García F, Fong K, Francisco Corral G, Cerezo González S, Freixinet Gilart J, García Arangüena L, García Barajas S, Girard P, Goksel T, González Budiño M, González Casaurrán G, Gullón Blanco J, Hernández Hernández J, Hernández Rodríguez H, Herrero Collantes J, Iglesias Heras M, Izquierdo Elena J, Jakobsen E, Kostas S, León Atance P, Núñez Ares A, Liao M, Losanovscky M, Lyons G, Magaroles R, De Esteban Júlvez L, Mariñán Gorospe M, McCaughan B, Kennedy C, Melchor Íñiguez R, Miravet Sorribes L, Naranjo Gozalo S, Álvarez de Arriba C, Núñez Delgado M, Padilla Alarcón J, Peñalver Cuesta J, Park J, Pass H, Pavón Fernández M, Rosenberg M, Ruffini E, Rusch V, Sánchez de Cos Escuín J, Saura Vinuesa A, Serra Mitjans M, Strand T, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, Van Schil P, Velasquez M, Wu Y, Yokoi K. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:681-692. [DOI: 10.1016/j.jtho.2015.12.114] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Revised: 12/01/2015] [Accepted: 12/29/2015] [Indexed: 12/01/2022]
|
26
|
Liao M, Li Y, Kianifard F, Obi E, Arcona S. Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis. BMC Nephrol 2016; 17:25. [PMID: 26936756 PMCID: PMC4776444 DOI: 10.1186/s12882-016-0238-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 02/19/2016] [Indexed: 11/25/2022] Open
Abstract
Background Cluster analysis (CA) is a frequently used applied statistical technique that helps to reveal hidden structures and “clusters” found in large data sets. However, this method has not been widely used in large healthcare claims databases where the distribution of expenditure data is commonly severely skewed. The purpose of this study was to identify cost change patterns of patients with end-stage renal disease (ESRD) who initiated hemodialysis (HD) by applying different clustering methods. Methods A retrospective, cross-sectional, observational study was conducted using the Truven Health MarketScan® Research Databases. Patients aged ≥18 years with ≥2 ESRD diagnoses who initiated HD between 2008 and 2010 were included. The K-means CA method and hierarchical CA with various linkage methods were applied to all-cause costs within baseline (12-months pre-HD) and follow-up periods (12-months post-HD) to identify clusters. Demographic, clinical, and cost information was extracted from both periods, and then examined by cluster. Results A total of 18,380 patients were identified. Meaningful all-cause cost clusters were generated using K-means CA and hierarchical CA with either flexible beta or Ward’s methods. Based on cluster sample sizes and change of cost patterns, the K-means CA method and 4 clusters were selected: Cluster 1: Average to High (n = 113); Cluster 2: Very High to High (n = 89); Cluster 3: Average to Average (n = 16,624); or Cluster 4: Increasing Costs, High at Both Points (n = 1554). Median cost changes in the 12-month pre-HD and post-HD periods increased from $185,070 to $884,605 for Cluster 1 (Average to High), decreased from $910,930 to $157,997 for Cluster 2 (Very High to High), were relatively stable and remained low from $15,168 to $13,026 for Cluster 3 (Average to Average), and increased from $57,909 to $193,140 for Cluster 4 (Increasing Costs, High at Both Points). Relatively stable costs after starting HD were associated with more stable scores on comorbidity index scores from the pre-and post-HD periods, while increasing costs were associated with more sharply increasing comorbidity scores. Conclusions The K-means CA method appeared to be the most appropriate in healthcare claims data with highly skewed cost information when taking into account both change of cost patterns and sample size in the smallest cluster.
Collapse
Affiliation(s)
- Minlei Liao
- KMK Consulting, Inc, 23 Headquarters Plaza, Morristown, NJ, 07960, USA.
| | - Yunfeng Li
- Outcomes Research Methods & Analytics, US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
| | - Farid Kianifard
- Biometrics, US Medical, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
| | - Engels Obi
- Rutgers Fellow, Cardiovascular/Respiratory, US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
| | - Stephen Arcona
- Outcomes Research Methods & Analytics, US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
| |
Collapse
|
27
|
Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WEE, van Meerbeeck J, Rami-Porta R, Asamura H, Ball D, Beer DG, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Erich Eberhardt WE, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim YT, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut T, Lyons G, Marino M, Marom EM, van Meerbeeck J, Mitchell A, Nakano T, Nicholson AG, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier JP, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas CF, Travis W, Tsao MS, Turrisi A, Vansteenkiste J, Watanabe H, Wu YL, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso PL, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Cavaco FA, Barrera EA, Arca JA, Lamelas IP, Obrer AA, Jorge RG, Ball D, Bascom G, Blanco Orozco A, González Castro M, Blum M, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Escobar Campuzano I, Vidueira IM, Araujo EF, García FA, Fong K, Corral GF, González SC, Gilart JF, Arangüena LG, Barajas SG, Girard P, Goksel T, González Budiño M, González Casaurrán G, Gullón Blanco J, Hernández Hernández J, Rodríguez HH, Collantes JH, Heras MI, Izquierdo Elena J, Jakobsen E, Kostas S, Atance PL, Ares AN, Liao M, Losanovscky M, Lyons G, Magaroles R, De Esteban Júlvez L, Gorospe MM, McCaughan B, Kennedy C, Melchor Íñiguez R, Miravet Sorribes L, Naranjo Gozalo S, de Arriba CÁ, Núñez Delgado M, Alarcón JP, Peñalver Cuesta J, Park J, Pass H, Pavón Fernández M, Rosenberg M, Rusch V, de Cos Escuín JS, Vinuesa AS, Serra Mitjans M, Strand T, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, Van Schil P, Velasquez M, Wu Y, Yokoi K. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 11:300-11. [PMID: 26723244 DOI: 10.1016/j.jtho.2015.10.008] [Citation(s) in RCA: 244] [Impact Index Per Article: 27.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 10/01/2015] [Accepted: 10/03/2015] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Small cell lung cancer (SCLC) is commonly classified as either limited or extensive, but the Union for International Cancer Control TNM Classification of Malignant Tumours seventh edition (2009) recommended tumor, node, and metastasis (TNM) staging based on analysis of the International Association for the Study of Lung Cancer (IASLC) database. METHODS Survival analyses were performed for clinically and pathologically staged patients presenting with SCLC from 1999 through 2010. Prognosis was compared in relation to the TNM seventh edition staging to serve as validation and analyzed in relation to proposed changes to the T descriptors found in the eighth edition. RESULTS There were 5002 patients: 4848 patients with clinical and 582 with pathological stages. Among these, 428 had both. Survival differences were confirmed for T and N categories and maintained in relation to proposed revisions to T descriptors for seventh edition TNM categories and proposed changes in the eighth edition. There were also survival differences, notably at 12 months, in patients with brain-only single-site metastasis (SSM) compared to SSM at other sites, and SSM without a pleural effusion showed a better prognosis than other patients in the M1b category. CONCLUSION We confirm the prognostic value of clinical and pathological TNM staging in patients with SCLC, and recommend continued usage for SCLC in relation to proposed changes to T, N, and M descriptors for NSCLC in the eighth edition. However, for M descriptors, it remains uncertain whether survival differences in patients with SSM in the brain simply reflect better treatment options rather than better survival based on anatomic extent of disease.
Collapse
Affiliation(s)
- Andrew G Nicholson
- Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK.
| | - Kari Chansky
- Cancer Research and Biostatistics, Seattle, WA, USA
| | - John Crowley
- Cancer Research and Biostatistics, Seattle, WA, USA
| | - Ricardo Beyruti
- Department of Thoracic Surgery, University of São Paulo, São Paulo, Brazil
| | - Kaoru Kubota
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Andrew Turrisi
- Department of Radiotherapy, Sinai Grace Hospital, Detroit, MI, USA
| | - Wilfried E E Eberhardt
- Department of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, University Hospital Essen, University Duisburg-Essen, Germany
| | - Jan van Meerbeeck
- Department of Oncology, Antwerp University Hospital, Edegem (Antwerp), Belgium
| | - Ramón Rami-Porta
- Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa and CIBERES Lung Cancer Group, Terrassa, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Huang L, Luo X, Shao J, Yan H, Qiu Y, Ke P, Zheng W, Xu B, Li W, Sun D, Cao D, Chen C, Zhuo F, Lin X, Tang F, Bao B, Zhou Y, Zhang X, Li H, Li J, Wan D, Yang L, Chen Y, Zhong Q, Gu X, Liu J, Huang L, Xie R, Li X, Xu Y, Luo Z, Liao M, Wang H, Sun L, Li H, Lau GW, Duan C. Epidemiology and characteristics of the dengue outbreak in Guangdong, Southern China, in 2014. Eur J Clin Microbiol Infect Dis 2015; 35:269-77. [DOI: 10.1007/s10096-015-2540-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 11/29/2015] [Indexed: 01/27/2023]
|
29
|
Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. J Rheumatol 2015; 43:88-96. [DOI: 10.3899/jrheum.150540] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/23/2015] [Indexed: 12/21/2022]
Abstract
Objective.Direct costs of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) have not been well characterized in the United States. This study assessed healthcare resource use and direct cost of AS and PsA, and identified predictors of all-cause medical and pharmacy costs.Methods.Adults aged ≥ 18 with a diagnosis of AS and PsA were identified in the MarketScan databases between October 1, 2011, and September 30, 2012. Patients were continuously enrolled with medical and pharmacy benefits for 12 months before and after the index date (first diagnosis). Baseline demographics and comorbidities were identified. Direct costs included hospitalizations, emergency room and office visits, and pharmacy costs. Multivariable regression was used to determine whether baseline covariates were associated with direct costs.Results.Patients with AS were younger and mostly men compared with patients with PsA. Hypertension and hyperlipidemia were the most common comorbidities in both cohorts. A higher percentage of patients with PsA used biologics and nonbiologic disease-modifying drugs (61.1% and 52.4%, respectively) compared with patients with AS (52.5% and 21.8%, respectively). Office visits were the most commonly used resource by patients with AS and PsA (∼11 visits). Annual direct medical costs [all US dollars, mean (SD)] for patients with AS and PsA were $6514 ($32,982) and $5108 ($22,258), respectively. Prescription drug costs were higher for patients with PsA [$14,174 ($15,821)] compared with patients with AS [$11,214 ($14,249)]. Multivariable regression analysis showed higher all-cause direct costs were associated with biologic use, age, and increased comorbidities in patients with AS or PsA (all p < 0.05).Conclusion.Biologic use, age, and comorbidities were major determinants of all-cause direct costs in patients with AS and PsA.
Collapse
|
30
|
Jiao P, Wei L, Song Y, Cui J, Zhang S, Han F, Yuan R, Liao M. Molecular cloning and immune responsive expression of LGP2 gene, a pivotal member of the RLR gene family from Muscovy duck Cairina moschata. Poult Sci 2015; 94:1170-6. [DOI: 10.3382/ps/pev082] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2015] [Indexed: 12/21/2022] Open
|
31
|
Korman NJ, Zhao Y, Li Y, Liao M, Tran MH. Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management. J DERMATOL TREAT 2015; 26:514-9. [PMID: 25886083 DOI: 10.3109/09546634.2015.1034074] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Pain, itching, burning and irritation are common symptoms of psoriasis but have not been well characterized by overall psoriasis severity. METHODS Using 2012 syndicated psoriasis patient survey data, 1050 subjects were classified into mild (n = 610) and moderate-to-severe (n = 440) psoriasis severity groups based on self-reporting. Demographics, comorbid medical conditions and patient-reported key symptoms (i.e. flare-up frequency, psoriasis-related pain, itching, burning, hurting, irritation) were compared between groups. Multiple regressions were employed to examine the impact of overall psoriasis severity on each key symptom, controlling for demographics and comorbidities. RESULTS Mild patients were older; more than 20% in both groups had joint pain and depression. Over 35 and 68% of the moderate-to-severe patients reported severe pain between or during flare-ups, respectively, and over 79% reported frequent bothersome itching. Controlling for between-group differences, moderate-to-severe patients had worse pain, were more likely to have continual flare-ups (odds ratio = 3.0) and flare-ups more than once monthly (odds ratio = 3.0), and reported more bothersome symptoms than patients with mild disease (all p < 0.05). CONCLUSION The presence and level of particular symptoms increase with self-reported disease severity in patients with psoriasis. Careful investigation of symptoms in tandem with clinical observation is important for effective psoriasis management.
Collapse
Affiliation(s)
- Neil J Korman
- a Department of Dermatology , University Hospitals Case Medical Center , Cleveland , OH , USA
| | - Yang Zhao
- b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA , and
| | - Yunfeng Li
- b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA , and
| | - Minlei Liao
- c KMK Consulting Inc . , Florham Park , NJ , USA
| | - Mary Helen Tran
- b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA , and
| |
Collapse
|
32
|
Ma KI, Du M, Liao M, Chen S, Yin G, Liu Q, Wei Q, Qin G. Evaluation of Wound Healing Effect of Punica granatum L Peel Extract on Deep Second-Degree Burns in Rats. TROP J PHARM RES 2015. [DOI: 10.4314/tjpr.v14i1.11] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
33
|
Zhang P, Xie MQ, Ding YQ, Liao M, Qi SS, Chen SX, Gu QQ, Zhou P, Sun CY. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice. Neuroscience 2015; 290:214-26. [PMID: 25637494 DOI: 10.1016/j.neuroscience.2015.01.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 01/16/2015] [Accepted: 01/18/2015] [Indexed: 12/12/2022]
Abstract
An earlier study has demonstrated that exogenous allopregnanolone (APα) can reverse the reduction of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNpc) of 3-month-old male triple transgenic Alzheimer's disease mouse (3xTgAD). This paper is focused on further clarifying the origin of these new-born TH-positive neurons induced by exogenous APα treatment. We performed a deeper research in another AD mouse model, 4-month-old male APPswe/PSEN1 double transgenic AD mouse (2xTgAD) by measuring APα concentration and counting immunopositive neurons using enzyme-linked immunosorbent assay (ELISA) and unbiased stereology. It was found that endogenous APα level and the number of TH-positive neurons were reduced in the 2xTgAD mice, and these reductions were present prior to the appearance of β-amyloid (Aβ)-positive plaques. Furthermore, a single 20mg/kg of exogenous APα treatment prevented the decline of total neurons, TH-positive neurons and TH/bromodeoxyuridine (BrdU) double-positive neurons in the SNpc of 2xTgAD mice although the decreased intensity of TH-positive fibers was not rescued in the striatum. It was also noted that exogenous APα administration had an apparent increase in the doublecortin (DCX)-positive neurons and DCX/BrdU double-positive neurons of subventricular zone (SVZ), as well as in the percentage of neuronal nuclear antigen (NeuN)/BrdU double-positive neurons of the SNpc in the 2xTgAD mice. These findings indicate that a lower level of endogenous APα is implicated in the loss of midbrain dopaminergic neurons in the 2xTgAD mice, and exogenous APα-induced a significant increase in the new-born dopaminergic neurons might be derived from the proliferating and differentiation of neural stem niche of SVZ.
Collapse
Affiliation(s)
- P Zhang
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China; Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - M Q Xie
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China; Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - Y-Q Ding
- Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - M Liao
- Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China; Department of Histology and Embryology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - S S Qi
- Department of Pharmacy, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China
| | - S X Chen
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - Q Q Gu
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China; Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - P Zhou
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China
| | - C Y Sun
- Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China; Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China.
| |
Collapse
|
34
|
Balani S, Bulychev A, Cohen L, Liao M, Xia C, Wang F, Li P, LeClair B, Bohnert T, Gan L, Zhou X, Bozon V, Prakash S. 162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70288-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res 2014; 46:753-60. [PMID: 24977660 DOI: 10.1055/s-0034-1376977] [Citation(s) in RCA: 118] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Formononetin is a naturally existing isoflavone, which can be found in the roots of Astragalus membranaceus, Trifolium pratense, Glycyrrhiza glabra, and Pueraria lobata. It was found to be associated with inhibition of cell proliferation and cell cycle progression, as well as induction of apoptosis in various cancer cell lines. However, the effect of formononetin on breast cancer cell metastasis remains unclear. In this study, we examined the effect of formononetin on the migration and invasion of breast cancer cells MDA-MB-231 and 4T1 in vitro and in vivo. Our data demonstrated that formononetin did not effectively inhibit the cell viability of MDA-MB-231 and 4T1 in 24 h with the concentration lower than 160 μmol/l. When treated with nontoxic concentration of formononetin, the migration and invasion of MDA-MB-231 and 4T1 cells were markedly suppressed by wound healing assay, chamber invasion assay, and in vivo mouse metastasis model. In vitro, formononetin reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and increased the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. Furthermore, the immunofluorescence and immunoblotting assays indicated that formononetin was very effective in suppressing the phosphorylation of Akt and PI3K. Collectively, these results suggest that formononetin inhibited breast cancer cell migration and invasion by reducing the expression of MMP-2 and MMP-9 through the PI3K/AKT signaling pathway. These findings demonstrate a potentially new therapeutic strategy of formononetin as anti-invasive agent for breast cancer.
Collapse
Affiliation(s)
- R Zhou
- Department of Chest and Breast Surgery, Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Xiamen, P. R. China
| | - L Xu
- Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, P. R. China
| | - M Ye
- Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China
| | - M Liao
- Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China
| | - H Du
- Department of Chest and Breast Surgery, Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Xiamen, P. R. China
| | - H Chen
- Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China
| |
Collapse
|
36
|
Krzakowski M, Mellemgaard A, Orlov S, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Kaiser R, Novello S, Douillard J, Reck M. Prior Taxane Use in the Lume-Lung 1 Phase III Trial and the Effect on Outcome Following 2Nd-Line Treatment with Nintedanib (Bibf 1120) and Docetaxel in Patients with Advanced Nsclc. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.33] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Su S, Gray GC, Lu J, Liao M, Zhang G, Li S. New "One Health" Strategies Needed for Detection and Control of Emerging Pathogens at Cantonese Live Animal Markets, China. Clin Infect Dis 2014; 59:1194-7. [DOI: 10.1093/cid/ciu553] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Qi W, Zhou X, Shi W, Huang L, Xia W, Liu D, Li H, Chen S, Lei F, Cao L, Wu J, He F, Song W, Li Q, Li H, Liao M, Liu M. Genesis of the novel human-infecting influenza A(H10N8) virus and potential genetic diversity of the virus in poultry, China. Euro Surveill 2014; 19. [DOI: 10.2807/1560-7917.es2014.19.25.20841] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Human infection with a novel influenza A(H10N8) virus was first described in China in December 2013. However, the origin and genetic diversity of this virus is still poorly understood. We performed a phylogenetic analysis and coalescent analysis of two viruses from the first case of influenza A(H10N8) (A/Jiangxi-Donghu/346-1/2013 and A/Jiangxi-Donghu/346-2/2013 and a novel A(H10N8) virus (A/chicken/Jiangxi/102/2013) isolated from a live poultry market that the patient had visited. The haemagglutinin (HA), neuraminidase (NA), PA subunit of the virus polymerase complex, nucleoprotein (NP), M and nonstructural protein (NS) genes of the three virus strains shared the same genetic origins. The origins of their HA and NA genes were similar: originally from wild birds to ducks, and then to chickens. The PA, NP, M, and NS genes were similar to those of chicken influenza A(H9N2) viruses. Coalescent analyses showed that the reassortment of these genes from A(H9N2) to A(H10N8) might have occurred at least twice. However, the PB1 and PB2 genes of the chicken A(H10N8) virus most likely originated from H7-like viruses of ducks, while those of the viruses from the case most likely stemmed from A(H9N2) viruses circulating in chickens. The oseltamivir-resistance mutation, R292K (R291K in A(H10N8) numbering) in the NA protein, occurred after four days of oseltamivir treatment. It seems that A(H10N8) viruses might have become established among poultry and their genetic diversity might be much higher than what we have observed.
Collapse
Affiliation(s)
- W Qi
- National and Local Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- These authors contributed equally to this article
| | - X Zhou
- These authors contributed equally to this article
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - W Shi
- These authors contributed equally to this article
- School of Basic Medical Sciences, Taishan Medical College, Taian, Shandong, China
| | - L Huang
- National and Local Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - W Xia
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - D Liu
- Network Information Center, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - H Li
- National and Local Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - S Chen
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - F Lei
- CAS Key Laboratory of Zoological Systematics and Evolution, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
| | - L Cao
- Guangzhou Center for Disease Control and Prevention, Guangzhou, China
| | - J Wu
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - F He
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - W Song
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - Q Li
- National and Local Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - H Li
- Nanchang Center for Disease Control and Prevention, Nanchang, China
| | - M Liao
- These authors contributed equally to this article
- National and Local Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - M Liu
- Nanchang Center for Disease Control and Prevention, Nanchang, China
- These authors contributed equally to this article
| |
Collapse
|
39
|
Niu L, Chen J, He T, Liao M, Yuan Y, Zeng J, Li J, Zuo J, Xu K. P0075 Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Eur J Cancer 2014. [DOI: 10.1016/j.ejca.2014.03.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Reck M, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Kaiser R, Novello S. 30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70031-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Wei L, Jiao P, Song Y, Han F, Cao L, Yang F, Ren T, Liao M. Identification and expression profiling analysis of goose melanoma differentiation associated gene 5 (MDA5) gene. Poult Sci 2013; 92:2618-24. [DOI: 10.3382/ps.2013-03064] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
42
|
Wu J, Zhu H, Song W, Li M, Liu C, Li N, Tang F, Mu H, Liao M, Li X, Guan W, Li X, Hua J. Identification of Conservative MicroRNAs in Saanen Dairy Goat Testis Through Deep Sequencing. Reprod Domest Anim 2013; 49:32-40. [DOI: 10.1111/rda.12217] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 06/20/2013] [Indexed: 01/28/2023]
Affiliation(s)
- J Wu
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - H Zhu
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - W Song
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - M Li
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - C Liu
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - N Li
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - F Tang
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - H Mu
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - M Liao
- College of Life Science Northwest A & F University Yangling China
| | - X Li
- Institute of Animal Science Chinese Academy of Agricultural Sciences Beijing China
| | - W Guan
- Institute of Animal Science Chinese Academy of Agricultural Sciences Beijing China
| | - X Li
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| | - J Hua
- College of Veterinary Medicine Shaanxi Centre of Stem Cells Engineering & Technology Key Lab for Animal Biotechnology of Agriculture Ministry of China Northwest A & F University Yangling China
| |
Collapse
|
43
|
Zhou S, Xu C, Zhang B, Feng S, Zhang L, Zou Y, Liao M. Natural IgG antibodies in normal rabbit serum are involved in killing of the ompP2 mutant of Haemophilus parasuis SC096 strain via the classical complement pathway. Vet J 2013; 196:111-3. [DOI: 10.1016/j.tvjl.2012.09.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2012] [Revised: 09/10/2012] [Accepted: 09/12/2012] [Indexed: 11/25/2022]
|
44
|
He X, Lu S, Liao M, Zhu X, Zhang M, Li S, You X, Chen J. Effects of age and size on critical swimming speed of juvenile Chinese sturgeon Acipenser sinensis at seasonal temperatures. J Fish Biol 2013; 82:1047-56. [PMID: 23464559 DOI: 10.1111/j.1095-8649.2012.12015.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2012] [Accepted: 11/04/2012] [Indexed: 05/26/2023]
Abstract
Changes in the critical swimming speed (Ucrit , cm s(-1) ) with ontogeny of 2·5-12·5 month-old juvenile anadromous Chinese sturgeon Acipenser sinesis were measured in a modified Blazka-type swimming tunnel. The absolute Ucrit increased with length, mass and age; the relative U(')crit (body lengths, s(-1) ), however, decreased. Juvenile A. sinesis did not display a parr-smolt transformation at the length or age threshold to tolerate full-strength seawater.
Collapse
Affiliation(s)
- X He
- Fisheries College, Huazhong Agricultural University, Wuhan 430070, China.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Jiao PR, Wei LM, Cheng YQ, Yuan RY, Han F, Liang J, Liu WL, Ren T, Xin CA, Liao M. Molecular cloning, characterization, and expression analysis of the Muscovy duck Toll-like receptor 3 (MdTLR3) gene. Poult Sci 2012; 91:2475-81. [PMID: 22991530 DOI: 10.3382/ps.2012-02394] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Toll-like receptor 3 (TLR3) is an important membrane-bound receptor for recognizing double-stranded RNA in innate immunity. In this study, we described the cloning and characterization of the Muscovy duck TLR3 (MdTLR3) gene. The full-length MdTLR3 cDNA (2,836 bp) encoded a polypeptide of 895 amino acids. The deduced amino acid sequence contained 4 main structural domains: a signal peptide, an extracellular leucine rich repeats domain, a transmembrane domain, and a Toll/IL-1 receptor domain. Quantitative real-time PCR analysis indicated that MdTLR3 mRNA was constitutively expressed in all sampled tissues of uninfected Muscovy duck except muscle. Expression of MdTLR3 in brain was significantly upregulated at 24 h (1.94-fold, P < 0.05), reached a peak at 48 h (4.64-fold, P < 0.05), and recovered to normal levels at 72 h postinfection with the H5N1 highly pathogenic avian influenza virus. In contrast, MdTLR3 expression was downregulated during the test period in spleen and lung. These results implicated MdTLR3 was a novel member of the TLR family, which is involved in the early stage of antiviral innate immunity.
Collapse
Affiliation(s)
- P R Jiao
- South China Agricultural University, Guangzhou, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Liao M, Bi Z, Liu X, Kang D, Fu J, Song Q, Freeman J, Jiang B, Jia Y. Condom use, intervention service utilization and HIV knowledge among female sex workers in China: results of three consecutive cross-sectional surveys in Shandong Province with historically low HIV prevalence. Int J STD AIDS 2012; 23:e23-9. [PMID: 22581891 DOI: 10.1258/ijsa.2009.009449] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Heterosexual transmission of HIV through contact with female sex workers (FSWs) is a growing concern for the HIV/AIDS epidemic in China. Using consecutive cross-sectional surveys, we examined the prevalence of HIV and sexually transmitted infections (STIs), risk behaviours, HIV knowledge and the utilization of intervention services among FSWs in Shandong Province. Of 3460 participants, half reported ever having STI-related symptoms, 57.8% had ≥7 clients in the last week, half reported inconsistent use of condoms with clients and 11.2% reported ever using illicit drugs. Consistent use of condoms with clients was associated with higher education, being 20-24 years of age, being recruited from hotels, having ever received free condoms and was inversely associated with STI-related symptoms. HIV-related knowledge was associated with higher education, ever testing for HIV and inversely associated with self-reported STI-related symptoms. The low rates of condom use, high number and frequent turnover of clients, high prevalence of self-reported STIs and drug use highlight the urgency for more effective intervention in these FSWs.
Collapse
Affiliation(s)
- M Liao
- Institute for AIDS/STD Control and Prevention, Shandong CDC, Jinan, Shandong Province, People's Republic of China
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Liao M, Ye F, Zhang B, Huang L, Xiao Q, Qin M, Mo L, Tan A, Gao Y, Lu Z, Wu C, Zhang Y, Zhang H, Qin X, Hu Y, Yang X, Mo Z. Erratum: Genome-wide association study identifies common variants at TNFRSF13B associated with IgG level in a healthy Chinese male population. Genes Immun 2012. [DOI: 10.1038/gene.2012.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
Liao M, Ye F, Zhang B, Huang L, Xiao Q, Qin M, Mo L, Tan A, Gao Y, Lu Z, Wu C, Zhang Y, Zhang H, Qin X, Hu Y, Yang X, Mo Z. Genome-wide association study identifies common variants at TNFRSF13B associated with IgG level in a healthy Chinese male population. Genes Immun 2012; 13:509-13. [DOI: 10.1038/gene.2012.26] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
49
|
Liu H, Wang L, Liao M, Lang J. Use of Proteomic Technology To Identify Urine Biomarkers in Patients with and without Endometriosis: A Preliminary Study. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Wang Q, Liao M. Systems toxicology used in nanotoxicology: Mechanistic insights into the hepatotoxicity of nano-copper particles from toxicogenomics. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|